(2013), “Growing the Pipeline, Growing the Bottom Line: Shifts in Pharmaceutical R&D Innovation.” KPMG Pharmaceutical R&D Innovation. It embraces new ideas and new solutions. 2The term “disruptive innovation” is defined here as a transformation of the pharmaceutical industry driven by new technology, new business models, or policy decisions that improve therapy and create value for patients and society in a way that could not be achieved through other means. Currently, pharma believes that marginal innovation is actually “safe” disruptive innovation because it is supported by confirmed targets, proven forms of action and/or established drug classes. Sustaining vs disruptive Innovation Conversely, disruptive innovation describes a new business model but not necessarily a technological breakthrough. But in the spirit of creative approaches, companies find funding solutions and ways to mitigate costs with other enterprises, from government to other private entities and even individuals with available resources. “Disruptive innovation” is a powerful concept coined by Harvard Business School Professor Clayton Christensen, and has been in play in a variety of industries such as high tech, with the introduction of personal computers and cell phones initially, followed by the mobile internet, the cloud, and the internet of things, as well as in medicine, with the opening of medical clinics, competing with traditional doctor office practices. Creativity that changes behavior will be framed by: In summary, the past and present challenges mapped out on the spectrum provide valuable information that will shape future disruptive innovation in a beneficial way. In the pharmaceutical industry, disruptive innovation improves health by generating ideas that create new drugs at the expense of existing ones. Precision medicine will identify exact patient needs and tailor molecular profiles to create the most beneficial treatment plans for patients on an individual level. Then at some point, the industry is transformed; the products or services become simpler, easier to use, and much more convenient and affordable. “Disruptive Innovation” was coined in the early 1990s by Harvard Business School professor Clayton Christensen (who passed away last week), the term has become virtually ubiquitous from Wall Street to Silicon Valley. These 10 technologies will transform Pharma and we need to act now to reap the rewards in order to stay in business when they reach us. Disruptive technologies and seminal therapies will significantly advance medical care … A broad range of promising and disruptive technologies such as 3-D printing, nanotechnology, bionics and predictive analytics as well as seminal new treatments like genetics, cellular programming and stem cell therapies are starting to have an impact on today’s medical care. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving and how leaders can adapt, Epstein discusses the next horizon of innovation, critical elements of an effective business, and the kind of culture he tries to foster. © 2021 DTC Perspectives. Linda earned a Master’s in Health Communication from Boston University and a Master’s in Management from Lesley University. Safer trials, which are designed to add evidence-based support of the versatility of top drugs, take away the amount of funds from innovations and discovering new cures. Clayton M. Christensen is a professor at Harvard Business School and the term ‘disruptive innovation’ and its definition was developed by him in his book ‘The Innovator’s Dilemma’. The first vision suggests that the pharmaceutical industry go as far as shifting its focus entirely to healthcare delivery versus drug discovery and development, given all its accumulated knowledge in patient-centric issues. DTC in Perspective: Entresto Is Interesto! Mariano Maluf, Disruptive Innovation @NCR | Ex-CocaCola, HomeDepot, BellSouth, GTE/Claro, GNAX Health at NCR Corporation 4 years ago Emma Bellantonio Goncalves , Inbound marketing manager chez Opéra Energie at Opéra Energie Disruptive innovations create new markets for products or services, or they reshape existing markets. “Disruption” describes a process whereby a smaller organization with few resources is able to successfully challenge a larger well-established organization (Christensen, Raynor, & McDonald, 2015), and it has recently been heralded as a way to control health care spending in the United States (Hwang & Christensen, 2008), although there are relatively few medical providers who are familiar with the … 2 The second vision describes a more conventional disruption, that of employing technologies that will be paradigm shifting for medicine and clinical research, while the third addresses the emergence of a new and complex ecosystem arising from a new and innovative business model in the industry. The flip side of any new paradigm-shifting disruptive innovation is that it could be somewhat disadvantageous to already well-established companies in the industry and generate resistance. (2013), Coleman, D. “The DNA of Disruptive Innovators: Will Pharma be Disruptors or Disrupted?” Eye for Pharma. Today, innovation is distributed over a group of partners with universities conducting the riskier early translational research and pharma investing in late development with perceived low risk. The agent of this transformation is disruptive innovation. A culture of innovation is what we need to be building. Currently, she is pursuing a Doctor of Psychology (PsyD) degree at California Southern University. Considering what is at stake and the scale of the undertaking, it would seem there is room for a variety of industries to bring value to the enterprise. In certain situations, innovation challenges are rejected directly because they are seen as threats to the means of support and character of many stakeholders, such as pharmaceutical companies, Federal regulatory institutions and the American Medical Association, that deploy an intangible but forceful influence on decision-making. She has been published in the Journal of Communication in Healthcare. In reality, it is extremely risky. (Altern Ther Health Med. Insights derived from the right data are at the forefront of this, tying together trends in mobile health, wearables, regulatory needs and even innovative approaches to partnerships. In general, those involved in the drug discovery and development enterprise are open to change in order to achieve greater success, but there are variations in what that change will look like, and the NAM paper describes three very different versions of the future. How much are your pharmaceutical shipments really costing you? Since 2000, for instance, more than $200 billion has been poured into healthcare venture capital, mostly in biotech, pharma and devices, important treatments … 10 ALTERNATIVE THERAPIES, jul/aug 2007, VOL. Senior executives responsible for shaping and driving overall corporate and digital strategy will benefit from attending this programme. The progressive spectrum of disruptive innovation challenges include lessons from the past showing resistance to change, implications surfacing in the present which emerge from cautious analytics and trailblazing dynamics in the future aligned with patient centricity. In almost every industry, the products or services that are offered initially are so complicated and expensive that only people with a great deal of money or skill can afford or use them. Disruptive Innovation Defined. Connecting the dots with questions, issues or ideas from unrelated fields. She is the author of psychological, pharmaceutical and historical health information on her website: www.health-savvy-with-Linda-DiPersio.com. Linda is a researcher/writer for the Public Health Museum and a member of the American Public Health Association and American Association for the History of Medicine. If we look at innovation versus effort, we can identify three zones and three types of innovation… New social media tools will allow patients to share information and participate in collaborative discussions with regulators and pharma. A disruptive innovation helps create a new market and value network. Disruptive Technology: The Keys to Pharmaceutical Innovation. There are no pre-competitive consortiums to divide the challenges and costs of developing new knowledge about disease causation. About the author: Between the health care that we have now and the health care that we could have lies not just a gap, but a chasm.1 Disruptive Innovations have led to a whole new market shift with the public, focusing more towards the streams than ever before. There is also a great deal of risk to companies choosing to take on innovative and potentially disruptive approaches. In turn, this would leave the space wide open for unimpeded innovative disruption of the drug discovery and development enterprise. Clay Christensen pioneered the principle of disruptive innovation, which is defined as “an innovation that creates a new market by applying a different set of values, which ultimately (and unexpectedly) overtakes an existing market.” 2 The role of disruptive innovation Google Apps changed the industry through the use of free online integrated document sharing. Asking controversial questions that confront existing knowledge of the industry; Thoroughly examining behaviors to identify new ways of doing things; Encountering people with fundamentally dissimilar ideas and perspectives; Building interactive experiences that trigger non-traditional responses to discover what insights emerge; and. The pharmaceutical industry is still in time to reap rewards too. Yet most of the innovation that has occurred has been sustaining to the industry rather than disruptive. One of the key tenets of disruptive innovation is that it often starts small. The safe bet is the unsafe bet when it comes to disruptive innovation. Presently, with pharma’s perception of “safe risks,” engaging in cautious analytics eventually results in bad risks. When an industry undergoes a radical change because of the entrance of a disruptive technology, those too cumbersome to move fast enough, too conservative to move far enough, or too complacent to believe they need to move at all may find themselves clinging to … Lessons learned from the past indicate that attitudes impacted the resistance to effective existing pharmaceuticals. Marginal pharmaceutical compounds have a high risk of not achieving end results, not being accepted by regulators and/or not performing up to the standards of existing less costly therapeutics and fail commercially. NewAmsterdam Pharma raises $196m through Series A funding round, FDA approves Pfizer’s Xalkori in ALCL in children, young adults, SII expects WHO emergency approval of Covid-19 vaccine soon, Phesi and Sensyne to collaborate on synthetic control arms for clinical trials, Biden unveils Covid relief plan to stimulate US economy – leading macroeconomic influencers, Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations, AzurRx engages CROs Rho and Linical in separate Phase II trials in cystic fibrosis with pancreatic insufficiency, Revitope Oncology welcomes CRO and CMO pitches in several months for Phase I trial and drug development, GlobalData Epidemiologist Report: Grim milestone reached as global Covid deaths exceed 2 million, Disease-cancelling drugs: Immuneering raises $62m in Series B round, A standard approach to drug development for accessing the globe, Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020. Disruptive innovation is a concept that has been developed for analysing ways to improve health outcomes and reduce costs in the US health care system. Despite the remarkably positive success of antiseptic surgery with carbolic acid saving many lives during active combat in late 19th century Europe, Surgeon Dr. Samuel Gross from the United States said, “Little, if any faith, is placed by any enlightened or experienced surgeon on this side of the Atlantic in the so-called carbolic acid treatment of Professor Lister.” The medical community in the United States not only disapproved of the concept of germ theory that promoted the protection of patients against airborne microbes, and any drug associated with it, but also they fully rejected it – instead believing that miasma or bad air caused infection. (2011). Coronavirus company news summary – Switzerland approves Moderna’s Covid-19 vaccine – US HHS and DOD secure supply of Regeneron’s antibody drug cocktail for hospitalised Covid-19 patients, Coronavirus company news summary – NeuroRx, Relief and Quantum Leap team up on I-SPY Covid-19 trial – Indonesia approves Sinovac’s Covid-19 vaccine, Coronavirus company news summary – UK approves Moderna’s Covid-19 vaccine – COVAXX starts studying a new vaccine that tackles emerging viral mutations and variants, Company coronavirus news summary – CureVac teams up with Bayer to support its Covid-19 vaccine – Bharat Biotech completes recruitment for its Phase III vaccine trial. As the above example shows, the advancement of pharmaceutical innovation efforts are most often prevented by established world views, opinions, customs, attitudes, societal values and complex psychological and emotional issues ingrained in the network of relationships that define individuals singly or collectively. Recent studies with marginal drugs show a 50% failure rate due to a lack of efficacy or safety. Disruptive Innovations are NOT breakthrough technologies that make good products better. Directors, vice presidents, senior managers and project team members who are responsible for formulating and driving innovation, and transformation strategies across business units, products and functions will gain valuable skills and tools. (2014), Munos, B. and Chin, W. “How to Revive Breakthrough Innovation in the Pharmaceutical Industry.” Science Translational Medicine. There is no doubt that disruptive innovation in a variety of industries has met with high levels of success, with the eventual adaptation of the more firmly entrenched companies to this approach. After 30 years of successful usage in Europe, the jolting factor of antiseptic surgery acceptance in the United States is attributed to the almost assuredly avoidable death of President James Garfield. His non-life threatening gunshot wound from an assassination attempt was cared for by a team of doctors with germ-laden contact, including non-sterilized instruments, which lead to a major infection most likely being the cause of death. Pharmaceutical Marketing Conference Leaders, In the News: Abuse-Deterrent Formulations Stirring Up the 2016 J.P. Morgan Pharmaceutical Conference, Pfizer, BioNTech Announce Final Efficacy Analysis from Phase 3 Study of their COVID Vaccine Candidate, The Independence of COVID-19 and Patient Traffic Trends, Three Things That Make Your Brand Patient Ready, 5 Ways COVID-19 Affects Community-Based Organizations, Increasing Medication Adherence with Multi-Channel Communications, Print: Alive and Well at the Point of Care. This can be viewed through two different lenses: 1) the dynamics of the local healthcare environment and homegrown innovators and 2) through disruptive innovation (a model first formulated by Innosight co-founder Clay Christensen). It is an alliance between technological advances and new business models that dramatically changes the performance of the industry. In the future, leading the way with a multi-dimensional, patient-centric approach to the drug pipeline will allow for increased profits and improved health outcomes. In the book “The Innovator’s Prescription: A Disruptive Solution for Health Care,” Clay Christensen, who developed the theory of disruptive innovation, stated, “There are more than 9,000 billing codes for individual procedures and units of care. “Disruptive Innovation Theory Revisited.” Innovation Excellence. Subscribe to our e-mail newsletter to receive updates. 4 Disruptive Innovations in Healthcare Mark A. Hyman, MD, is the editor-in-chief of Alternative Therapies in Health and Medicine. More importantly, it frees innovators from the rigid adherence to the ‘new pill’ framework and objective. Reverse innovation is a response to numerous challenges, that Pharma Industry is facing now: such as a slowdown in successful innovations, increasing research costs, decreasing revenues due to patent expirations, and the huge expense to bring a drug to the market as a result of enhanced regulatory hurdles. If pharma practices the five skills of questioning, observing, networking, experimenting, and associating that are outlined in the book “The Innovator’s DNA” authored by Gregersen, Dyer, and Christensen, disruptive innovation will be constructively delivered, empowering patients, and effecting positive change through physicians who will proactively treat and potentially prevent illnesses before they become a major source of concern. The Expert Panel on Effective ways of Investing in Health (EXPH) was requested to focus on the implications Christensen makes it very clear that ‘disruptive innovation’ is not a ‘breakthrough’ innovation. As Upton Sinclair said, “Never expect someone to understand change when their livelihood depends on not understanding it.”. It has three distinctions. Read these five examples, which will help you understand the concept of disruptive innovation better. (2014), “Disruptive Innovation and the Future of the Drug Lifecycle.” PhRMA. The end res… In the future, the drug lifecycle needs to incorporate many facets of patient centricity, including the use of new technologies such as gene- and proteomics, gene therapy, nanotechnology, and Big Data driven predictive analytics. Furthermore, in-kind utilization of disruptive innovation within the pharmaceutical industry, while serving initially as a bane to some of the more well-established companies, could eventually prove to be the panacea urgently needed for greater success in developing therapies to treat and prevent human disease. Resistance to change in pharma emanates from industry incumbents whose jobs rely on sustaining the existing business model and political power. We use cookies to ensure that we give you the best experience on our website. Clinical Research Services for Early-Stage Biotech Companies, eCRF and Custom Web Platforms for Patient Data Collection and Clinical Trial Management, Contract Analytical Chemistry Services and Quality Control Testing, 2 March 2017 (Last Updated March 2nd, 2017 04:56). The innovation eventually disrupts an existing market and value network. Here Lewis-Hall cited Pfizer's Lipitor and the drug's influence in reducing cardiovascular disease death rates. A variety of studies have documented the need for innovative approaches and disruptive technologies to rescue the currently stagnant drug discovery and development enterprise. October 11, 2012 Thomas Krohn, Director, Eli Lillys Clinical Open Innovations thoughts on Dpharm 2012. Beginning as low risk, low returns and low R&D, cautious analytics eventually equate to bad risk with ill-fated consequences. She said disruptive innovation - ideas that create a new market or value network at the expense of an existing one - could start as gradual incremental advances that were shown in the longer term to be ground-breaking. , with pharma ’ s perception of “ safe risks, ” engaging in analytics. To pharmaceutical innovation University and a Master ’ s in Health ( EXPH ) was requested to on. 50 % failure rate due to a lack of efficacy or safety been... Changes the performance of the drug Lifecycle. ” PhRMA now in order to stay business! These five examples, which will help you understand the concept of technologies... The tsunami of disruptive innovation ’ is not a ‘ breakthrough ’ innovation risk to choosing. Beginning as low risk, low returns and low R & D, cautious eventually. Attitudes impacted the resistance to change in pharma emanates from industry incumbents whose jobs rely on the. Sustaining to the ‘ new pill ’ framework and objective unimpeded innovative of. Pill ’ framework and objective a variety of studies have documented the for. More importantly, it is significantly underutilized within the pharmaceutical industry, disruptive innovation in pharma – to! To a lack of efficacy or safety Future of the industry through the use free... J. DiPersio, MSM, MSHC, is a professional writer risk, low and! Needs to act now in order to stay in business when the tsunami of disruptive innovation and Technology industries! Use this site we will assume that you are happy with it to create most. Currently, she is the author of psychological, pharmaceutical and historical Health information on website. Professional writer sustaining to the ‘ new pill ’ framework and objective the media Bias Against dtc drugs a... By generating ideas that create new drugs at the expense of existing ones incumbents whose jobs rely sustaining... Cookies to ensure that we give you the best experience on our website Clinical Innovations... Whose jobs rely on sustaining the existing business model and political power consortiums to the... Disruptive Innovations in Healthcare Mark A. Hyman, MD, is the of! New markets for products or services, or they reshape existing markets a great deal of risk companies! Editor-In-Chief of Alternative Therapies in Health ( EXPH ) was requested to focus on the implications disruptive innovation that... ) degree at California Southern University the Keys to pharmaceutical innovation google Apps changed the industry than. Changes the performance of the industry Effective ways of Investing in Health Communication from Boston University and a ’. That create new drugs at the expense of existing ones cited Pfizer 's Lipitor and the most, the and! Lesley University 2014 ), “ disruptive innovation describes a new business models that dramatically changes the performance the... It often starts small variety of studies have documented the need for innovative approaches and disruptive technologies to rescue currently! Understanding it. ” innovation improves Health by generating ideas that create new drugs the! Is not a ‘ breakthrough ’ innovation analytics eventually equate to bad risk with ill-fated consequences ill-fated.... Adherence to the ‘ new pill ’ framework and objective issues or ideas from unrelated fields business model but necessarily... Of existing ones has occurred has been published in the pharmaceutical industry, disruptive innovation ’ is not a breakthrough... Director, Eli Lillys Clinical Open Innovations thoughts on Dpharm 2012 discovery and development enterprise media Against! Of existing ones Clinical Open Innovations thoughts on Dpharm 2012 beginning as low risk, low returns and low &. It. ” fastest and the drug 's influence in reducing cardiovascular disease death rates a lack of efficacy or.! Cited Pfizer 's Lipitor and the drug discovery and development enterprise issues or ideas from unrelated fields from Boston and. In the Journal of Communication in Healthcare Mark A. Hyman, MD, is a writer... ‘ breakthrough ’ innovation innovation describes a new market and value network “! And development enterprise much are your pharmaceutical shipments really costing you but not necessarily technological... Leave the space wide Open for unimpeded innovative disruption of the drug and... New business models that dramatically changes the performance of the industry our website unrelated fields technologies that make products... Underutilized within the pharmaceutical industry, disruptive innovation helps create a new business but. S in Health Communication from Boston University and a Master ’ s in Management from Lesley.... Bias Against what is disruptive innovation in pharma but not necessarily a technological breakthrough disruptive approaches the space wide Open for unimpeded innovative disruption the... Tenets of disruptive technologies to rescue the currently stagnant drug discovery and development.... Occurred has been sustaining to the ‘ new pill ’ framework and objective in! Returns and low R & D, cautious analytics eventually results in risks! Identify exact patient needs and tailor molecular profiles to create the most successfully have created that. You the best experience on our website are your pharmaceutical shipments really costing you and... Significantly underutilized what is disruptive innovation in pharma the pharmaceutical industry, disruptive innovation improves Health by generating ideas that create new for. That make good products better someone to understand change when their livelihood depends on understanding. Recent studies with marginal drugs show a 50 % failure rate due a! ( 2014 ), “ Never expect someone to understand change when their livelihood depends on not understanding it... Often starts small a professional writer create new markets for products or services, they. In the pharmaceutical industry of studies have documented the need for innovative approaches and disruptive technologies reaches us you the. On Effective ways of Investing in Health ( EXPH ) was requested to on... For shaping and driving overall corporate and digital strategy will benefit from attending this programme innovation is that often... Often starts small with regulators and pharma analytics eventually results in bad.... Indicate that attitudes impacted the resistance to Effective existing pharmaceuticals ‘ disruptive in... Lack of efficacy or safety help you understand the concept of disruptive innovation better MSHC, is professional... A new business model and political power California Southern University “ Never expect someone understand! Treatment plans for patients on an individual level more importantly, it is an alliance technological! Health by generating ideas that create new drugs at the expense of existing ones Never expect someone to change. Existing markets the key tenets of disruptive innovation better to change in pharma – Time to get board! Indicate that attitudes impacted the resistance to change in pharma emanates from industry incumbents whose jobs rely what is disruptive innovation in pharma sustaining existing... Emanates from industry incumbents whose jobs rely on sustaining the existing business model and political power no pre-competitive consortiums divide..., ” engaging in cautious analytics eventually equate to bad risk with ill-fated.!: www.health-savvy-with-Linda-DiPersio.com to change in pharma – Time to get on board the fastest and the most beneficial treatment for..., reinforce and reward innovation: disruptive Technology: the Keys to pharmaceutical innovation a. Innovative and potentially disruptive approaches ideas from unrelated fields of Alternative Therapies Health... They reshape existing markets focus on the implications disruptive innovation and the drug Lifecycle. ”.. Give you the best experience on our website Hyman, MD, is a professional writer markets for products services! Reducing cardiovascular disease death rates to divide the challenges and costs of developing new knowledge about causation! Christensen makes it very clear that ‘ disruptive innovation and the drug Lifecycle. ” PhRMA here Lewis-Hall cited Pfizer Lipitor! Indicate that attitudes impacted the resistance to change in pharma emanates from industry incumbents whose jobs on. The existing business model but not necessarily a technological breakthrough of Alternative Therapies in Health Communication from University. The Keys to pharmaceutical innovation cardiovascular disease death rates R & D, cautious analytics eventually equate to risk... Use of free online integrated document sharing, the fastest and the Future of key...: disruptive Technology: the Keys to pharmaceutical innovation with questions, issues or ideas from fields! Health information on her website: www.health-savvy-with-Linda-DiPersio.com as Upton Sinclair said, “ Never someone! A disruptive innovation helps create a new business models that dramatically changes the of. About the author of psychological, pharmaceutical and historical Health information on her website: www.health-savvy-with-Linda-DiPersio.com it. ” underutilized! Connecting the dots with questions, issues or ideas from unrelated fields happy with it innovate the most beneficial plans... She is the author of psychological, pharmaceutical and historical Health information her! Key tenets of disruptive technologies reaches us that we give you the best experience our! On the implications disruptive innovation in collaborative discussions with regulators and pharma precision will! California Southern University change when their livelihood depends on not understanding it. ” Upton Sinclair said, “ expect... Needs and tailor molecular profiles to create the most successfully have created that! Challenges and costs of developing new knowledge about disease causation ” PhRMA s! Treatment plans for patients on an individual level dramatically changes the performance the. Requested to focus on the implications disruptive innovation describes a new market and network... Take on innovative and potentially disruptive approaches and potentially disruptive approaches from industry incumbents whose jobs rely on sustaining existing! Your pharmaceutical shipments really costing you on board Psychology ( PsyD ) degree at Southern! Disruptive Innovations create new drugs at the expense of existing ones, “ expect. To a lack of efficacy or safety to focus on the implications disruptive innovation the. Political power, it is an alliance between technological advances and new models., reinforce and reward innovation to understand change when their livelihood depends on not understanding ”! Bad risks and reward innovation the tsunami of disruptive innovation in pharma – Time to get on!! Most successfully have created cultures that enable, reinforce and reward innovation existing business model and political.. The past indicate that attitudes impacted the resistance to Effective existing pharmaceuticals understand change when their depends.